MAGENTUM 1 HeartMate 3 LVAS: A Single Center Prospective Controlled Study (MAGENTUM 1)

Inclusion Criteria: * patients implanted with HeartMate 3 LVAS irrespective of an indication * data collection for major thrombophilic mutations including anti-phospholipid syndrome and lupus anticoagulant testing prior to low-intensity protocol anticoagulation initiation has been performed * patient will be compliant with an anticoagulation management in a judgment of the investigator * patient in stable condition with anticipated home discharge Exclusion Criteria: * absence of an informed consent * presence of additional MCS e.g. ECMO, RVAD in less than 7 days prior to low- intensity protocol anticoagulation initiation * known history of major thrombotic event e.g. DVT * presence of other than biological valve prosthesis in aortic position * left atrial appendage in patients with atrial fibrillation or flutter not addressed by resection or exclusion at a time of the implant * hemodynamically significant or symptomatic carotid artery stenosis prior to low-intensity protocol anticoagulation initiation